Clinical trials
CAR clinical trials
Below are recruiting car clinical trials, each written for real people, not researchers. We’re tracking 733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07502859RecruitingEarly Phase 1
BEN301 injection for autoimmune diseases
This trial tests an investigational drug called BEN301 for people with certain autoimmune diseases like systemic sclerosis, rheumatoid arthritis, Sjögren's syndrome, or myositis. It aims to see if the drug can help control the disease and improve symptoms.
Beijing, Beijing MunicipalityAges 18–70 - NCT07297667RecruitingPhase 1
CAR T-cell therapy for certain advanced solid tumors
This trial tests a new treatment called GCAR1, which uses your own immune cells (T-cells) to find and attack cancer cells that have a specific marker called GPNMB. It is for people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if this therapy can help shrink or control the tumor.
Calgary, AlbertaAges 15 years+ - NCT07593482RecruitingPhase 2
Conditioning chemo before CAR-T for large B-cell lymphoma
This trial compares two standard chemotherapy combinations (bendamustine or fludarabine plus cyclophosphamide) given before a CAR-T cell treatment to see which one helps the CAR-T cells work better and causes fewer side effects.
AarauAges 18 years+ - NCT06430736RecruitingPhase 2
Tocilizumab before or during CAR-T therapy
This study tests whether giving tocilizumab (a drug that calms inflammation) before CAR-T cell therapy helps prevent side effects. It compares using it ahead of time versus only when needed. You may be eligible if you are scheduled for CAR-T therapy for lymphoma, leukemia, or myeloma.
Bern, Canton of BernAges 18 years+ - NCT07200102RecruitingPhase 1
Selinexor after CAR-T for high-risk multiple myeloma
This study tests whether taking selinexor after CAR-T cell therapy can help keep multiple myeloma from coming back. It is for people whose myeloma is high-risk or still has signs of disease after CAR-T.
St Louis, MissouriAges 18 years+ - NCT05633615RecruitingPhase 2
Testing new drug options after CAR T for aggressive lymphoma
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
Tucson, ArizonaAges 18 years+ - NCT07825064RecruitingPhase 2
Cevostamab combination after CAR T-cell therapy for multiple myeloma
This trial tests a new drug, cevostamab, combined with two standard medicines (pomalidomide and dexamethasone) for people with multiple myeloma who have already had CAR T-cell therapy. It aims to see if this combination can help control the cancer better.
GreifswaldAges 18 years+ - NCT07532525RecruitingPhase 1
Pomalidomide after CAR T for B-cell cancer
This trial tests whether the drug pomalidomide, given as a pill, can help people with B-cell leukemia or lymphoma who have recently received CAR T-cell therapy. The goal is to see if pomalidomide can keep the cancer from coming back, and it may be an option for those whose cancer is not growing but still needs management.
Ann Arbor, MichiganAges 18 years+ - NCT07200089RecruitingPhase 1
IL-7 treatment after CAR-T therapy for multiple myeloma
This trial tests whether a drug called NT-I7 (a lab-made immune booster) can help people with multiple myeloma who have already received a CAR-T cell therapy called cilta-cel. It's for patients whose myeloma has come back or hasn't responded well to treatment.
St Louis, MissouriAges 18 years+ - NCT07344311RecruitingPhase 1
CAR-T cell therapy for advanced prostate cancer
This trial tests a new immunotherapy called A-CAR032, which uses your own immune cells to attack prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer that has progressed after other treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04440436RecruitingPhase 1/Phase 2
IM19 study for relapsed or refractory non-Hodgkin lymphoma
This trial tests whether IM19 can safely and effectively treat non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It is for adults with certain lymphoma markers and good overall functioning.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05323201RecruitingPhase 1/Phase 2
B7H3 CAR-T therapy for advanced liver cancer
This trial tests an immune therapy made from your own blood cells (CAR-T) to treat advanced, unresectable liver cancer. It’s designed for people whose tumor has a specific marker called B7H3 and who meet blood, organ, and safety requirements.
Xuzhou, JiangsuAges 18–70 - NCT05445011RecruitingPhase 1
FLT3-targeted CAR-T for relapsed or resistant AML
This trial tests an engineered immune cell treatment (CAR-T) made to target FLT3, for adults with acute myeloid leukemia (AML) that has come back or did not respond to standard treatment. It aims to control the leukemia when options have been limited.
Wuhan, HubeiAges 18–70 - NCT05626400Recruiting
CAR T for relapsed T-ALL or T-LBL with CD7
This trial tests a type of immune therapy (CAR T cells) called Senl-T7 in people whose T-cell leukemia or lymphoma has come back or did not respond. It aims to target cancer cells that carry a marker called CD7.
Beijingcun, HebeiAges 2–70 - NCT05620732Recruiting
CAR-T treatment for advanced stomach or pancreatic cancer
This trial tests a customized immune-cell treatment (CAR-T) for advanced stomach or pancreatic cancer that cannot be removed by surgery. It aims to use cells engineered to target a specific tumor marker to shrink cancer or slow its growth.
Shenzhen, GuangdongAges 18–75 - NCT05594797RecruitingPhase 2
BCMA CAR-T for multiple myeloma that came back or stopped working
This trial tests a one-time BCMA CAR-T cell treatment for people with multiple myeloma that relapsed or did not respond well to prior treatments. It may help by training your own immune cells to recognize and attack myeloma cells.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05521802RecruitingPhase 1/Phase 2
Testing a new CAR-T therapy for relapsed myeloma
This Phase 1/2 study tests C-CAR088, a lab-made immune therapy, in people with multiple myeloma that has come back or did not respond. It is for patients who have already had several standard treatments and whose disease is still measurable.
TianjinAges 18 years+ - NCT05842707RecruitingPhase 1/Phase 2
Cord blood CAR cells for hard-to-treat B-cell lymphoma
This Phase 1/2 study tests cord blood–derived CAR NK cells that are designed to attack lymphoma cells marked with CD19 and/or CD70. It is for people whose B-cell non-Hodgkin lymphoma has come back or did not respond to prior treatment, including CAR-T when applicable.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06180174RecruitingPhase 1
CD19-targeted CAR-T cells for relapsed B-cell lymphoma
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06248697RecruitingEarly Phase 1
CAR-T cells targeting MSLN with PD-1/CTLA-4 blockers for advanced solid tumors
This trial tests a new type of immune cell therapy (CAR-T cells) that target a protein called MSLN on cancer cells, and also release a special antibody to block two other proteins (PD-1 and CTLA-4) that cancers use to hide from the immune system. It is for people with advanced solid tumors like non-small-cell lung cancer or mesothelioma who have not responded to standard treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06333275Recruiting
Boosting immunity after CAR-T therapy
This trial checks if giving vaccines after CAR-T cell therapy can help your immune system fight off preventable diseases. It is for adults with certain blood cancers who are about to get CAR-T treatment.
BernAges 18 years+ - NCT06339255Recruiting
Observational study on CAR-T therapy for lymphoma
This study observes patients with certain lymphomas who are already eligible for standard CAR-T cell therapy in Italy. It aims to gather real-world information about how these treatments work.
MilanAges 18 years+ - NCT05652920RecruitingPhase 1/Phase 2
CAR T-cell therapy for liver cancer that has GPC3
This early-phase study tests modified immune T cells (CAR T cells) to treat hepatocellular carcinoma (HCC), a type of liver cancer, when the tumor shows a marker called GPC3. It may help shrink tumors or slow cancer growth, especially after other treatments have stopped working.
Beijing, Beijing MunicipalityAges 18–70 - NCT06087341RecruitingPhase 1
CAR T-Cell Therapy for Advanced Sarcoma in Young People
This trial tests a special type of immune cell (called a CAR T-cell) that is trained to attack sarcoma cells. It is for children, teens, and young adults up to age 40 whose sarcoma has not responded to standard therapy. The treatment is given directly into the tumor, and the goal is to see if it is safe and how well it works.
MadridAges Up to 30 years
Hear when a new CAR trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for car?
- Yes. Clin2 currently lists 733 recruiting car studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a car trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a car trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.